Board-Level Capital Strategy for Seed–Series A Biotech & Health Innovation Companies
Aligning Institutional Capital and Federal Funding for Coherent, Credible Raises.
The Source of Capital Friction
Capital challenges are rarely about demand; they’re about alignment. They emerge from misalignment within the capital strategy itself.
In early-stage biotech, federal funding, equity strategy, and milestone design are often developed in parallel. From an investor’s perspective, they are evaluated as one integrated system.
When these elements are misaligned, friction quickly arises, slowing momentum, weakening positioning, and delaying funding outcomes.
Strategic Capital Advisory
I work with founders and boards of Seed–Series A biotech and health innovation companies to align capital sequencing, milestone architecture, and investor positioning, particularly where non-dilutive federal funding and venture capital intersect. The focus is not on preparing materials, but on ensuring the underlying strategy holds together under investor scrutiny.
How We Think About Capital Strategy
Effective capital formation is built on three integrated elements:
Capital Sequencing
Aligning federal and equity pathways to support de-risking and timing
Milestone Credibility
Designing milestones that support both scientific progress and investor expectations
Capital Risk Alignment
Ensuring burn, timelines, and funding pathways are structurally coherent
When these are aligned, the capital narrative becomes clear, and investor confidence follows.
Clients We’ve Helped
“Idong is a born leader. I have worked with many professionals while a senior scientist at CDC and Idong’s work ethics are pristine, she is easily adjustable to a given situation. Her ability to go out of her way to help others has made her stand out. I was impressed by her ability to handle any situation calmly and patiently, even with the toughest clients. This natural skill of hers has helped successfully manage complex contracts and exceed productivity goals. Any organization would be lucky to have her management and leadership skills. As a project manager and scientific consultant, Idong earns my highest recommendation.”
Margo Riggs
PHPS Outbreak Investigations Lead
Who Is This For:
This work is designed for companies that are:
- Preparing for or actively in a Seed or Series A raise
- Navigating both federal funding and equity capital pathways
- Refining milestone strategy to support valuation and investor expectations
- Experiencing friction or uncertainty in investor conversations
Engagement Model:
Advisory engagements are structured, selective, and aligned with active capital formation.
- 6-month strategic advisory engagements
- Focused on capital alignment during the raise
- Limited number of clients at any given time
A Structured Approach to Capital
Capital strategy is not just about raising funds. It is about structuring the business for credible, sustained growth. If you are preparing to raise and want your capital strategy to hold together at the structural level, I welcome a conversation.